Pivoting to Allogeneic CAR-T Therapies with Celyad Oncology’s CMO, Dr. Charlie Morris

We love to hear from our listeners. Send us a message.

Celyad Oncology’s CMO, Dr. Charlie Morris, shares the benefits and challenges of the allogeneic approach versus the autologous approach and why a non-gene edited shRNA approach may result in better efficacy and safety for CAR-T therapies.

Subscribe to the podcast!
Apple | Spotify | YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn